Lisa Olson - Feb 15, 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Title: Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Stock symbol
DNTH
Transactions as of
Feb 15, 2022
Transactions value $
$0
Form type
4
Date filed
2/17/2022, 04:17 PM
Previous filing
Sep 20, 2021
Next filing
May 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +100K $0.00 100K Feb 15, 2022 Common Stock 100K $3.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022.

Remarks:

Title: Head of Research and Chief Scientific Officer